Sarcopenia recognises insulin resistance and obesity as risk factors, and is frequently associated with cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD).
SUMMARY Background
Sarcopenia recognises insulin resistance and obesity as risk factors, and is frequently associated with cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD).
Aim
To test the prevalence of sarcopenia and its relation with the severity of fibrosis (main outcome) and the entire spectrum of liver histology in patients with NAFLD.
Methods
We considered 225 consecutive patients with histological diagnosis of NAFLD (Kleiner score). The skeletal muscle index (%) (total appendicular skeletal muscle mass (kg)/weight (kg) 9 100), a validated measure of sarcopenia, was assessed by bioelectrical impedance analysis. Sarcopenia was defined as a skeletal muscle mass index ≤37 in males and ≤28 in females.
Results
The prevalence of sarcopenia showed a linear increase with the severity of fibrosis, and severe fibrosis (F3-F4) was more than doubled in sarcopenia (48.3% vs. 20 .4% in fibrosis ≤F2, P < 0.001). After adjusting for confounders, the association of sarcopenia with severe fibrosis was maintained (OR 2.36, CI 1.16-4.77, P = 0.01), together with age > 50 (OR 6.53, CI 2.95-14.4, P < 0.001), IFG/Diabetes (OR 2.14, CI 1.05-4.35, P = 0.03) and NASH (OR 13.3, CI 1.64-108.1, P = 0.01). Similarly, a significant association was found between sarcopenia and NASH (P = 0.01), steatosis severity (P = 0.006), and ballooning (P = 0.01), but only the association with severe steatosis was maintained (OR 2.02, CI 1.06-3.83, P = 0.03) after adjusting for confounders.
Conclusions
In Western patients with NAFLD, with high prevalence of metabolic disorders and advanced liver disease, sarcopenia was associated with the severity of fibrosis and steatosis, independently of hepatic and metabolic risk factors. Studies are needed to assess the impact of interventions to reduce sarcopenia on NAFLD progression. INTRODUCTION Non-alcoholic fatty liver disease (NAFLD) is found in about 20-30% of the general population 1 and is a growing cause of morbidity and mortality worldwide. 2, 3 Two recent European and US studies on large cohorts of subjects with histologically diagnosed NAFLD showed that the severity of liver fibrosis is the main determinant of long-term prognosis, driving both hepatic and extrahepatic events and mortality. 2, 3 Obesity and insulin resistance (IR), both highly prevalent in NAFLD, play a key role in the pathogenesis and in the progression of liver damage towards cirrhosis and end-stage complications. 4 Other putative mechanisms of disease progression have been proposed (vitamin D deficiency, 5 hyperuricemia, 6 industrial fructose intake, 7 menopausal status, 8 etc.); they are frequently shared by NAFLD, obesity and IR, further blurring the complex interplay between NAFLD and metabolic dysfunction. Sarcopenia has been recently proposed as an additional key factor, again shared between NAFLD, obesity and IR. Sarcopenia is a pathological disorder characterised by generalised loss of skeletal muscle mass and strength. In the past, it was only regarded as part of ageing 9 ; more recently, it was recognised as a progressive disease frequently associated with cardiometabolic disorders, including diabetes mellitus, metabolic syndrome and cardiovascular disease. 10 In keeping with these data, recent studies in community-based Asian populations showed that sarcopenia is also associated with the presence of NAFLD, diagnosed by non-invasive scores 11 or by computed tomography (CT), 12 as well as with its severity, assessed by noninvasive scores, 11 or with histology in selected NAFLD cohorts. 13 Poor nutritional status is common in advanced liver disease, where sarcopenia becomes a well-known predictor of mortality, [14] [15] [16] The association of NAFLD severity with sarcopenia in Asian populations [11] [12] [13] requires (i) confirmatory evidence in other ethnic groups, and (ii) a precise definition of the possible effects of cirrhosis and shared metabolic risk factors on defective muscle mass. The aims of this study were to assess the prevalence of and the risk factors for sarcopenia throughout the entire spectrum of liver disease and its comorbidities in a Western population of patients with biopsy-proven NAFLD.
PATIENTS AND METHODS

Patients
This prospective study involved 225 relatively healthy and free-living consecutive patients with biopsy-proven NAFLD recruited at the Gastrointestinal & Liver Unit of Palermo University Hospital, fulfilling all the inclusion and exclusion criteria detailed below. Inclusion criteria were: a histological diagnosis of NAFLD on a liver biopsy done within 6 months of enrolment, showing steatosis (>5% of hepatocytes) with/without necroinflammation and/or fibrosis, including cirrhosis. The prebiopsy assessment of NAFLD was based on chronically elevated ALT for at least 6 months and alcohol consumption of <20 g/day in the year before (also confirmed by a questionnaire). Exclusion criteria were: (i) decompensated cirrhosis (jaundice, presence of ascites or encephalopathy); (ii) hepatocellular carcinoma; (iii) liver disease of different or mixed aetiology (excessive alcohol consumption, hepatitis C, hepatitis B, autoimmune liver disease, Wilson's disease, hemochromatosis, a1-antitrypsin deficiency); (iv) human immunodeficiency virus infection; (v) regular use of steatosis-inducing drugs (steroid, amiodarone, tamoxifen, etc.), as assessed at interview; (vi) active intravenous drug addiction.
The study was carried out in accordance with the principles of the Helsinki Declaration and its appendices, and with local and national laws. Approval was obtained from the hospital Internal Review Board and its Ethics Committee, and written informed consent was obtained from all patients.
Clinical and laboratory assessment
Clinical and anthropometric data were collected at the time of enrolment, before liver biopsy. Waist circumference was measured at the mid-point between the lower border of the rib cage and the iliac crest. Visceral obesity was diagnosed in the presence of waist circumference ≥102 cm in males and ≥88 cm in females. 17 The diagnosis of arterial hypertension was based on the following criteria: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg (measured three times within 30 minutes, in the sitting position and using a brachial sphygmomanometer), or use of blood-pressure-lowering agents. The diagnosis of impaired fasting glucose (IFG) and of type 2 diabetes was based on the revised criteria of the American Diabetes Association, using a value of fasting blood glucose ≥100 to <126, and ≥126 mg/dL, respectively. 18 In patients with a previous diagnosis of type 2 diabetes, current therapy with insulin or oral hypoglycaemic agents was documented. Data on intake of statins, angiotensin-receptor inhibitors/angiotensin-receptor blockers (ACE-Is/ARBs), metformin, calcium channel blockers and fibrates were recorded.
A 12-hour overnight fasting blood sample was drawn at the time of enrolment to determine the serum levels of ALT, triglycerides, plasma glucose and insulin. Insulin resistance (IR) was determined according to the homoeostasis model assessment (HOMA) method, 19 as:
Insulin resistance (HOMA-IR) = Fasting insulin (lU/mL) 9 Fasting glucose (mmol/L)/22.5.
Histological assessment
Slides of NAFLD were coded and read by one pathologist (D.C.), who was unaware of the patients' identity and history. A minimum length of 15 mm of biopsy specimen or the presence of at least 10 complete portal tracts was required. 20 Steatosis was assessed as the percentage of hepatocytes containing fat droplets (minimum 5%). The Kleiner classification 21 was used to grade steatosis, lobular inflammation, and hepatocellular ballooning, and to stage fibrosis from 0 to 4. NASH was considered to be present when steatosis, ballooning and lobular inflammation were all present.
ELECTRICAL BIOIMPEDENTIOMETRY
On the same day of liver biopsy, all patients had their regional muscle mass measured by bioelectrical impedance analysis (BIA), an easy, timesaving and cost-effective bedside technique for assessing body composition. Bioelectrical impedance analysis applies an alternating electrical current to determine the two components of impedance in the human body, that is, resistance, R, and reactance Xc. In electrophysiological terms, resistance correlates negatively with the quality of body fluids (body water and fat-free mass, FFM) through which the current flows, while reactance, that is, the capacitive reactance in biological tissues where cell membranes behave as capacitors, correlates positively with body cell mass. Resistance R and reactance Xc were measured using a single-frequency impedance analyzer (EFGElectroFluidGraph+ AKERN). Impedance measurements were obtained using the standard positions for the outer and inner electrodes on the right hand and foot under controlled condition. The skeletal muscle mass index, a validated measure of sarcopenia, 22 was calculated as follows: skeletal muscle mass index (%) = total appendicular skeletal mass (kg)/body weight (kg) 9 100. Sarcopenia was defined as a skeletal muscle mass index ≤37 in males and ≤28 in females, these cut-offs representing skeletal muscle mass index values below one standard deviation of values measured in young healthy adults. 22 BIA also provides a measure of the phase angle, that is, the phase shift of the flow of the electric current, dependent of the amount of water in the tissues. The phase angle is positively associated with reactance and negatively associated with resistance. 23 A low value indicates cell death or cell disruption, and is a negative prognostic marker in several clinical conditions, including liver disease. 24 A conservative cut-off value below 5.4°w
as taken as indicative of sarcopenia. 24 Statistics Continuous variables were summarised as mean AE s.d., and categorical variables as percentage. The t-test, the chi-square and the ANOVA test were used when appropriate. Multiple logistic regression models were used to assess the factors independently associated with the presence of sarcopenia, F3-F4 fibrosis, NASH, grade 3 steatosis, presence of ballooning and grade 2/3 lobular inflammation (dependent variables, coded as 0 = absent or 1 = present). As candidate risk factors, we selected age (continuous), age >50, gender, BMI, presence of visceral obesity, baseline ALT, triglycerides, blood glucose, insulin, HOMA, IFG/diabetes, arterial hypertension, metformin treatment, use of ACE-Is/ARBs, calcium channel blockers and fibrates, bioelectrical phase angle (for histological outcomes only) and sarcopenia (for histological outcomes only).
To avoid the effect of colinearity, HOMA-score, blood glucose, insulin levels and IFG/diabetes, or waist circumference and BMI, or bioelectrical phase angle and sarcopenia, or the NAS score and its components, were not included in the same multivariate models.
Variables associated with the dependent variable at univariate analysis (probability threshold, P ≤ 0.10) were included in the multivariate regression models. Regression analyses were performed using SPSS.
RESULTS
Study population
The baseline characteristics of the 225 NAFLD patients are shown in Table 1 . Mean age was 48, with a higher prevalence of males (63%). Seventy-one per cent of patients fitted the criteria for visceral obesity, while IFG/ diabetes and hypertension were observed in 45% and 33% of subjects respectively. The use of metformin, ACE-Is/ARBs and statins was recorded in 19.1%, 24.4% and 9.3% of patients respectively. No patients had heart failure or chronic kidney disease ≥ stage III.
At liver biopsy, two-thirds of patients had grade 2-3 steatosis; NASH was diagnosed in 81% of cases, and finally one patient in three had F3-F4 fibrosis (F4 in 15% of cases).
Sarcopenia is associated with visceral obesity index and insulin resistance Sarcopenia was diagnosed by the skeletal muscle index in 43.6% of total cases (Table 1 ), more frequently in older patients and in females, with insulin resistance, obesity (namely visceral obesity) and/or altered glucose regulation/diabetes and/or raised blood pressure, without differences in relation to dyslipidemia (Table 2) . By logistic regression analysis visceral obesity (OR 5.32, CI 2.37-11.9, P < 0.001), and higher HOMA values (OR 1.18, CI 1.04-1.34, P = 0.01) remained independently associated with sarcopenia.
A phase angle below the cut-off of 5.4°was found only in 13 cases, and was significantly associated with older age (59.4 AE 8.1 years vs. 47.6 AE 13.4 in subjects defined as nonsarcopenic, P = 002), female gender (11.9% vs. 2.1, P = 0.002), visceral obesity (7.5% vs. 1.5, P = 0.08), higher blood glucose (129.0 AE 55.0 mg/dL vs. 102.0 AE 30.3, P = 004), higher HOMA (5.29 AE 1.46 vs. 4.24 AE 2.52, P = 01) and IFG/Diabetes (8.8% vs. 3.2, P = 0.08). Only older age (OR 1.06, C.I. 1.00-1.16, P = 04) was confirmed at multivariate analysis (Table 3 ).
Sarcopenia and liver damage
Severe fibrosis. Figure 1 shows the prevalence of sarcopenia for each stage of fibrosis, reporting a progressive increase from patients without fibrosis (fibrosis F0, 22.2%), to F1 (34.9%), to F2 (43.7%), F3 (66.6%) and finally F4 (60.0%) (P = 0.002).
Severe liver fibrosis (stage F3-F4) was associated with older age, higher BMI, visceral obesity, higher baseline blood glucose, insulin and HOMA values, IFG/diabetes, arterial hypertension, NASH, lower bioelectrical phase angle and sarcopenia. Specifically, the prevalence of severe fibrosis was significantly higher in patients with sarcopenia compared to those without (48.3% vs. 20.4%, P < 0.001) (Figure 2 ). By multiple logistic regression analysis, this association was maintained (OR 2.36, CI 1.16-4.77, P = 0.01), together with age >50 (OR 6.53, CI 2.95-14.4, P < 0.001), IFG/Diabetes (OR 2.14, CI 1.05-4.35, P = 0.03) and NASH (OR 13.3, CI 1.64-108.1, P = 0.01). After additional adjustment for the use of drugs significantly associated at univariate analysis (P < 0.10) with F3-F4 fibrosis (ACE-Is/ARBs, metformin, calcium channel blockers and statins) sarcopenia remained significantly associated with severe fibrosis (OR 2.36, CI 1.15-4.84, P = 0.01). The independent association of sarcopenia with F3-F4 fibrosis was also confirmed (OR 1.76, CI 1.03-3.73, P = 0.04) after replacing IFG/ Diabetes with HOMA, Finally in presence of sarcopenia, the prevalence of severe fibrosis was significantly higher both in patients with visceral obesity (46.0% vs. 30.9% in nonsarcopenic, P = 0.05) and in non-obese patients (44.4% vs. 7.1%, P = 0.002) (Figure 2) . Similarly, the prevalence of severe fibrosis was systematically associated with sarcopenia in patients with (56.6% vs. 34.6%, P = 0.02) or without IFG/Diabetes (33.3% vs. 11.5%, P = 0.003). In a sensitivity analysis, the role of cirrhosis as driver of the association between sarcopenia and severe fibrosis was tested by repeating the analysis after exclusion of cases with F4 fibrosis (n = 35). Sarcopenia was present in 24/36 cases, and the association of sarcopenia with F3 fibrosis was confirmed (OR 2.88, CI 1.19-6.97, P = 0.01) after adjusting for age >50 years, visceral obesity, IFG/diabetes, hypertension and NASH.
Finally, when sarcopenia was replaced by the bioelectrical phase angle in multivariable analysis, this parameter was not systematically associated with F3-F4 fibrosis after adjustment for confounders (OR 0.91, CI 0.63-1.32, P = 0.62). NASH, steatosis, ballooning and lobular inflammation. The prevalence of NASH was higher in the presence of sarcopenia (88.7% vs. 76.3% in nonsarcopenic cases, P = 0.01) (Figure 3) , as was the prevalence of grade 3 steatosis (38.3% vs. 24.6%, P = 0.006), and ballooning (88.6% vs. 75.8%, P = 0.01), but not of grade 2-3 lobular inflammation (46% vs. 39.1%, P = 0.28) (Figure 3 ). However, after adjusting for confounders only grade 3 steatosis (OR 2.02, CI 1.06-3.83, P = 0.03; adjusted for visceral obesity), but not ballooning (OR 1.28, CI 0.51-3.17, P = 0.58; adjusted for gender, visceral obesity and IFG/Diabetes) and NASH (OR 0.98, CI 0.39-2.45, P = 0.97; adjusted for gender, age >50 years, visceral obesity, IFG/Diabetes and arterial hypertension) were confirmed as independently associated with sarcopenia. These results were maintained after additional adjustments for the use of drugs associated with the histological features at univariate analysis (P < 0.10) (data not shown). The bioelectrical phase angle was not associated with grade 3 steatosis (7.1 AE 1.1°vs. 6.9 AE 0.9°in subjects with lower grades of steatosis, P = 0.15), ballooning (7.0 AE 0.9°vs. 7.1 AE 1.2°in the absence of ballooning, P = 0.62) and NASH (6.9 AE 0.9°vs. 7.1 AE 1.1°in non-NASH, P = 0.14), but with grade 2-3 lobular inflammation (6.7 AE 0.8°vs. 7.2 AE 1.0°in subjects with lower grades of inflammation, P < 0.001). This association remained marginally significant after adjustment for confounders (OR 0.72, CI 0.50-1.03, P = 0.07).
DISCUSSION
In a Western cohort of patients with histological diagnosis of NAFLD, we found that sarcopenia, mainly related to obesity and IR, is associated with the severity of liver fibrosis and steatosis. Notably, these results were obtained after adjusting for metabolic and liver risk factors.
Sarcopenia is not only a "para-physiological" feature related to ageing; but there is also growing evidence that low muscle mass is a condition strictly associated with cardiometabolic alterations. 10 In our study on patients with high prevalence of metabolic disorders, we observed a close relationship between sarcopenia and both obesity and IR. This relationship is in agreement with data reported in other clinical settings, 25 but, contrary to what expected, the presence of sarcopenia was independent of age and gender. This conflicting result might be related to the low mean age of our population, but might also suggest that disease severity accelerates and offsets the effects of age. No independent association was also observed between sarcopenia and the use of drugs as metformin, ACE-Is/ARBs and calcium channel blockers, reported to affect muscle mass. [26] [27] [28] [29] To our knowledge, this is the first report linking sarcopenia with liver damage in NAFLD in a Caucasian population. Specifically, we found an inverse link between sarcopenia and severity of hepatic fibrosis, also confirmed after exclusion of patients with cirrhosis. Notably, although NAFLD shares with sarcopenia a link with both obesity and IFG/Diabetes, the relationship between sarcopenia and severe fibrosis was confirmed after adjustment for demographic, metabolic and histological confounders. Of note, the link between sarcopenia and the severity of fibrosis was observed in both obese and nonobese patients. Our data on the association between sarcopenia and fibrosis in NAFLD are in agreement with those reported in studies in Asian populations, where a link was found between sarcopenia and the severity of hepatic fibrosis assessed by both histology, 13 liver stiffness at transient elastography 13 and non-invasive scores.
11
Our study also reported an inverse relationship between sarcopenia and the presence of NASH, severe steatosis and ballooning. Of note, after adjustment for demographic and metabolic risk factors the link of sarcopenia with the severity of steatosis was confirmed, not those with ballooning and NASH. These data suggest a prominent role of sarcopenia on fibrosis and steatosis. Our results partly confirm previous studies, reporting an association between the presence of steatosis, diagnosed by either computed tomography or non-invasive scores, and sarcopenia, 11, 12 whereas Koo et al. 13 also reported an independent link between NASH and sarcopenia. Differences in the baseline characteristics of the populations and in the definition of sarcopenia could explain conflicting results. Although this study was not designed to clarify the pathogenic link between sarcopenia and the severity of liver fibrosis, several hypotheses may be put forward to mechanistically explain this association. Both NAFLD and sarcopenia recognise obesity, as well as IR as welldefined risk factors. We may speculate that IR/obesity favour the development of sarcopenia, and that chronic liver disease, via reduced IGF-1, and increased proinflammatory cytokines, participates to sarcopenia impairment. 30, 31 On the other hand, sarcopenia per se might directly contribute to liver damage via the reduction in myokines, like interleukin-6 32 and irisin, 33 which showed a protective effect towards IR, steatosis and inflammation. An independent role of sarcopenia on liver damage is supported by cohort studies in patients with advanced liver disease, showing that sarcopenia is able to predict liver-related mortality. [14] [15] [16] We also found an association between low bioelectrical phase angle and both severe fibrosis and grade 2-3 lobular inflammation, in agreement with the evidence about lower bioelectrical phase angle as predictor of death in patients with cirrhosis. 24 The associations, however, were not confirmed after adjusting for confounders, and further studies are needed to clarify this issue. The phase angle is dependent on both extracellular water and intracellular water, and a recent validation study showed that it may largely vary according to age and BMI. 34 The relatively young age and the high BMI of our populations might remarkably shift the vector of impedance and reactance to values different from those observed in other cohorts. From a clinical point of view, our study prompts to include the assessment of sarcopenia in the baseline multidisciplinary evaluation of NAFLD patients. This condition, marker and/or cause of liver damage and metabolic alterations, might represent a new target for the management of NAFLD. However, further longitudinal studies are necessary to prove the prognostic value of sarcopenia in NAFLD patients, and the effect of its correction on hepatic and extra-hepatic alterations in this clinical setting. Consistent with this hypothesis, two recent studies reported a link between sarcopenia and mortality, 14-16, 35, 36 although limited to patients with advanced cirrhosis. Some limitations of this study must be acknowledged. First, the cross-sectional nature of this study makes it impossible to interpret any cause-effect relationship. In addition, sarcopenia was defined by skeletal muscle mass index measured by BIA, not by the gold standard methods. However, several studies have validated the use of BIA vs. DXA [37] [38] [39] and vs. magnetic resonance, 22 the results we obtained are in agreement with the literature, thus supporting the use of a cheaper and easy-available instrument to assess skeletal muscle mass index in NAFLD population. Another limitation is the lack of data on physical activity and gait speed or grip strength that could help characterise sarcopenia in a functional way, not only on the basis of the relative muscle mass. US guidelines reinforce the need to support the diagnosis of sarcopenia with the demonstration of low gait speed coupled with an objectively measured low muscle mass. 40, 41 A further methodological question is to what extent these data may be extrapolated to different populations. Our study included a cohort of Italian patients enrolled at a tertiary care centre, which may be different, in terms of both metabolic features and severity of liver disease, from the majority of prevalent cases of NAFLD in the general population and/or in different geographical areas. Finally, we cannot rule out that the association between sarcopenia and liver fibrosis hid other pathogenic patterns common to NAFLD and metabolic disorders.
In conclusion, we demonstrated that in a cohort of Western patients with NAFLD and at high prevalence of metabolic disorders and liver damage, sarcopenia is a marker/risk factor for the severity of steatosis and fibrosis, independently of well-known hepatic and metabolic risk factors. Sarcopenia may be corrected by adequate nutritional support 42 ; further studies are needed to assess the impact of sarcopenia correction on hepatic and metabolic complications in NAFLD patients.
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